The Supreme Court on Monday rejected a bid by notorious “pharma bro” Martin Shkreli to hear his appeal of a $64 million financial penalty on the fraudster.
Shkreli had been ordered to pay that penalty for blocking competition to a lifesaving drug whose price he had raised by more than $700 per pill.
Shkreli’s request that the Supreme Court take his appeal of a federal court decision on a lawsuit by the Federal Trade Commission was his last chance to overturn that penalty, which was related to the drug Daraprim.
KEY POINTS